CTNM
NASD Contineum Therapeutics, Inc. Class A$7.08 ↑ +0.00 (+0.00%) Trading Up from the previous close of $7.08, $0.79 below the day’s high of $7.87
- YTD change
- -38.06%
- vs 20-day SMA
- -40.87%
- vs 200-day SMA
- -48.16%
Price ranges
Price & Performance
-5.40 (-40.60%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 67.8% away from all-time highs of $22.00
- CTNM is down 38% since the beginning of the year
- CTNM is down 43% over the past 12 months
- CTNM is down 46% over the past 1 month
- 9% of all CTNM investors are betting against CTNM
CTNM reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -36.6%.
- Previous minute
- +$0.00
- Last hour
- -$0.05
- Last 5 days
- -46.28%
- vs 8-day SMA
- -33.34%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.